Business Wire

Exclusive Group Transitions Leadership Team for Next Stage of Growth

4.10.2018 10:00:00 EEST | Business Wire | Press release

Share

Exclusive Group, the global value-added services and technologies (VAST) group, today announced Andy Travers as its new SVP Worldwide Sales and Marketing. The ex-Fortinet and RSA executive will be responsible for leading the next phase of Exclusive’s growth strategy to build the world’s biggest specialist VAD in cybersecurity and cloud transformation with targeted revenues of $10bn over the next 5 years.

The appointment coincides with the news that Exclusive Group’s current COO, Barrie Desmond, has decided to step down at the end of 2018 to pursue other interests. Affectionately dubbed ‘Disruptive Desmond’, he has played a key role in developing Exclusive’s go-to-market proposition, market positioning and sales growth over the last 7 years.

Andy Travers is a 25-year veteran of IT channel sales excellence, achieving success at reseller, VAD and global vendor organisations. As SVP of Worldwide Sales and Marketing, Travers will be responsible for steering Exclusive to unprecedented revenues, heading up strategic alliances with major vendors, developing key relationships with GSIs and taking executive control of global services. His previous roles include SVP and VP Sales positions on both sides of the Atlantic for Fortinet, as well as VP EMEA stints at F5 Networks and, most recently, RSA Security.

Commenting on the changes Olivier Breittmayer, Exclusive Group’s CEO said, “Following our recent investment from Permira funds we set ourselves high expectations for executing against our new growth strategy. Andy has the skills and experience necessary to contribute to us achieving our goals and understands our unique culture and values having been in the orbit of Exclusive working with our vendors and channel partners for many years. We are delighted to have him onboard.

“Barrie’s decision to stand down at the end of the year is totally respected by myself and the board. We’ve worked well together these past 7 years, architecting and driving the growth of this business and telling the story only we can tell. It’s been a great journey together and we wish him all the best for the future.”

Commenting on his appointment Andy Travers said, “Exclusive has earned a worldwide reputation for doing what no other VAD has been able to do – delivering genuine value-add at scale. I’m joining at a pivotal time for the business as we commit to exploiting the global opportunities around cybersecurity and cloud transformation to reach another step-change in growth. The investors and management team have developed a winning strategy and now it’s all about the execution. I’m delighted to be joining and really looking forward to helping achieve the next phase of growth.”

Desmond and Travers will work closely together over the next few months to ensure a smooth transition.

Commenting on his decision to leave Exclusive at the end of the year, COO Barrie Desmond said, “My work here is done. We’ve had an incredible journey and built a VAD that continues to disrupt, grow sales at an extraordinary rate and expand its footprint at an astonishing tempo. Along the way we’ve reinvented Distribution and redefined value. But now it’s time for the next generation of disruptors to take on the challenge of growing the world’s largest specialist VAD.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cohesive
Jon Bawden
+44 (0) 1291 626200
exclusivegroup@wearecohesive.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release

Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila

PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye